Drug intelligence / Profile preview

StrataMGT

Development stage: Unknown
Lead developer: Stratpharma
Administration: Topical

Overview

StrataMGT is a film-forming, semi-permeable silicone gel developed for the management of symptoms associated with vulvar lichen sclerosus (VLS). Classified as an FDA-registered Class I medical device, it is composed of medical-grade silicone polymers that create a hydrophobic, semi-occlusive, and bacteriostatic barrier on the vulvar tissue. This barrier provides hydration while allowing gas exchange and protecting the mucosa from external irritants such as urine, infection, and friction. Research indicates that StrataMGT may also suppress pro-inflammatory cytokines, thereby reducing inflammation and improving quality of life for patients with VLS. It is currently being evaluated in clinical trials led by Dr. Andrew T. Goldstein as a non-steroidal therapeutic option.

Brand names: StrataMGT

Beyond the preview

Go deeper on StrataMGT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StrataMGT.

Explore the full profile